The Administrative Core provides essential infrastructure linking our member core and clinical trials development teams. It provides expert guidance and oversight to SWOG, develops and maintains our Operations Center organizational structure and policies, and supports an up-to-date set of Standard Operating Procedures that cover all aspects of the Network Group's activities. Administrative Core duties include: ? Establishing conditions for, maintaining records of, and monitoring SWOG institutional and individual membership; ? Operationalizing clinical and translational trial proposals and protocols, continuously searching for development process improvements ? Serious Adverse Event collection and monitoring, as well as patient safety reporting ? Quality assurance and onsite auditing ? Developing, conducting, and assessing training programs ? Tracking and adjudicating financial conflicts of interest ? Establishing, maintaining, and monitoring institutional and individual regulatory requirements ? Meetings management ? Group financial management ? Communications ? Publications and presentations management ? Contracting ? Legal support ? Administering tissue banking, including release of specimens ? Interacting with key members of the NCTN and other organizations The Administrative Core works seamlessly with other SWOG components which have different funding (e.g., our Statistical and Data Management Center), and it oversees SWOG interactions with a variety of NCTN and external components.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180888-07
Application #
9922258
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Herbst, Roy S; Redman, Mary W; Kim, Edward S et al. (2018) Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol 19:101-114
Othus, Megan; Sekeres, Mikkael A; Nand, Sucha et al. (2018) Relative survival following response to 7?+?3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. Leukemia :
Mongiovi, Jennifer M; Zirpoli, Gary R; Cannioto, Rikki et al. (2018) Associations between self-reported diet during treatment and chemotherapy-induced peripheral neuropathy in a cooperative group trial (S0221). Breast Cancer Res 20:146
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Statler, Abby; Othus, Megan; Erba, Harry P et al. (2018) Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. Blood 131:2782-2788
Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153

Showing the most recent 10 out of 249 publications